Cargando…
Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs
Reimbursement decisions on new oncology drugs are now often made while uncertainty remains about a drug's risk–benefit profile. One consequence of this is a delay in patient access to valuable new medicines. We share our perspectives on strategies to mitigate sources of uncertainty in the healt...
Autores principales: | Solà-Morales, Oriol, Volmer, Timm, Mantovani, Lorenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Routledge
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346722/ https://www.ncbi.nlm.nih.gov/pubmed/30719243 http://dx.doi.org/10.1080/20016689.2018.1562861 |
Ejemplares similares
-
Payer Perspectives on Health Technology Assessment
por: Watkins, John B.
Publicado: (2012) -
Pharmaceutical Technology Assessment: Perspectives from Payers
por: Leung, Musetta Y., et al.
Publicado: (2012) -
Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations
por: Binder, Louise, et al.
Publicado: (2022) -
Assessing payer perspectives on health information exchange
por: Cross, Dori A, et al.
Publicado: (2016) -
Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs
por: Epstein, Robert S
Publicado: (2021)